Abstract
cancer treatment. To do this requires quantitative mathematical models to predict opti-23 mal dose and frequency for a particular drug, and experimental model systems such as 24 three-dimensional organoids that accurately recapitulate the tumor microenvironment 25 and heterogeneity. However, tracking the spatial dynamics of multiple cell types in 26 three-dimensions can be a significant challenge in terms of time and throughput. Here 27
we develop a two-dimensional system that allows for simple tracking of cell populations 28 via fluorescence microscopy for modeling spatial dynamics in tumors. We first develop 29 multiple 4T1 breast cancer cell lines resistant to varying concentrations of doxorubicin, 30 and demonstrate how well mixed and spatially heterogeneous populations expand in a 31 two-dimensional colony. We subject cell populations to varied dose and frequency of 32 chemotherapy and measure colony growth radius and populations. We then build a 33 mathematical model to describe the dynamics of both chemosensitive and 34 chemoresistant populations, where we determine which number of doses can produce 35 the smallest tumor size based on parameters in the system. In the future, this system 36 Cells were allowed to settle for 24 hours before a PBS wash. Fresh medium was sub-143 sequently added to fill the whole well to initiate colony expansion. The tip can be insert-144 ed into the center or near the edge of the drop and the resulted resistant subcolony will 145 be observed at the corresponding location within the big colony (Fig 1, case II (Fig 2A) . While the IC 50 of wild type 4T1 cells was about 2 μM, the two 182 representative resistant cell lines we created were able to maintain viability at much 183 higher drug concentrations. For 4T1-Dox (3 μM), 4T1 cells that were cultured in the 184 presence of 3 μM of Dox, we observed minimal reduction in cell viability even at 100 μM, 185
which was the highest concentration tested due to the limited drug solubility. We next assessed the effect of initial cell density on the growth of the colonies over time. 200
Specifically, maintaining the seeded drop volume constant at 20 μL, increasing seeded 201 cell number (all sensitive cells) from 10K to 50K resulted in an over 2x increase in initial 202 colony diameter (Fig 2B) . However, the colony expansion rates indicated by the change 203 in colony diameter within a fixed time period (slope of the growth curves) were similar 204 despite the difference in initial colony diameter. Reduction in serum level impeded colo-205 ny expansion, however, where a 10x reduction in serum level was required to achieve a 206 significant reduction in colony growth rate ( Fig S1) . increasing the initial proportion of resistant cells had minimal impact on colony expan-219 sion in the absence of any doxorubicin treatment (Fig 2C, Fig S2 A-C) . Interestingly, for 220 colonies with cells that were more resistant to doxorubicin (4T1-Dox [800 nM], which 221 grow at 800 nM doxorubicin), a marked reduction in colony expansion was observed 222 when the majority of seeded cells were resistant even in the absence of drug treatment 223 (Fig S2 F) . For all tested conditions, doxorubicin treatment had minimal impact on colo-224 ny expansion during the initial stage while the reduction in colony expansion was more 225 pronounced during later time points (Fig 2C, D, Fig S2) . Taken day was achieved in each scenario. Gentle PBS wash was done for several times after 269 each dose to remove waste in culture and fresh media with drug was then added for 270 next dose. We found that when holding the cumulative treatment constant, colony ex-271 pansion kinetics were not affected by altered dosing schedule or altered serum level in 272 the media (Fig 4) . Hence, the cumulative treatment but not the dose level determined 273 the treatment efficacy in a serum-independent manner. Taken together, our model sys-274 tem can be utilized to identify a lower but effective drug concentration and can be uti-275 lized to test cumulative treatment regimes. To quantitatively understand the dynamics of chemosensitive and chemoresistant cells 289 subject to different dosing strategies, we built a mathematical model. In this model, 290 chemosensitive (N s ) and chemoresistant (N r ) cells are initially mixed at a given ratio andthen assumed to exponentially grow at rates μ s and μ r , respectively (Fig 5A) . To subject 292 cells to chemotherapy, we used our experimentally determined doxorubicin dose-293 response viability curve for wildtype and resistant 4T1 cells (Fig 2A) . Thus, cells after a 294
given interval of time would have the population level N = V(x) * e a , where V(x) is the 295 viability value for cells at a particular dose x, and a is the growth rate (a scaled time in-296 terval of t=1 is assumed here for simplicity). In the case of multiple doses, each dose is 297 fractionated across a smaller interval, but repeated for multiple intervals, keeping the 298 Here we observed that the to-315 tal number of chemosensitive cells was reduced as we increased the initial dosage for a 316 single dose, as expected, while the amount of chemoresistant cells was not affected by 317 chemotherapy dose (Fig. 5B) . This latter result is because we simulated highly resistant 318 cells such as 4T1 (Dox 3uM) are viable at all chemotherapy doses tested. We then cal-319 culated the fraction of resistant cells across multiple doses and initial conditions (Fig.  320   5C ). For high doses, such as in a maximum tolerated dose (MTD) approach, resistant 321 populations eventually dominate the cell population as previously noted. Next, we set 322 sensitive and resistant cells at a 1:1 initial ratio and assumed similar growth rates. We 323
found that when varying the number of doses applied, the fraction of resistant cells and 324 total cell number as compared to a single dose (termed "gain") was a function of the ini-325 tial starting dose of chemotherapy used (Fig. 5D ). Low concentrations of chemotherapy 326 resulted in populations with a lower fraction of resistant cells when comparing multiple 327 doses to a single dose (low gain). In turn, multiple doses also resulted in larger total cell 328 populations (high gain), which can be interpreted as larger tumor sizes. However, at 329 high concentrations of chemotherapy, the relationship was observed to be reversed. 330
Higher levels of chemotherapy with multiple doses led to an increased fraction of re-331 sistant cells and smaller total cell number. The relationship between increasing resistant 332 cell fraction and smaller total cell number was inversely proportional, such that there 333 was no particular number of doses or starting dose that would allow for beneficial opti-334 mization of both measures (Fig 5E) . Lastly, dependent on the initial resistant cell frac-335 tion, we found that sharper gains could be obtained with less numbers of initial resistantcells. This trend was also further magnified when resistant cells grew slower (Fig 5F) . A 337 common clinical situation is when initial resistant cell populations are low and slow 338 growing, and in these cases the effect of metronomic dosing may be magnified. In 339 summary, based on the kinetics of our 2D model system, this simple mathematical 340 model can predict a critical concentration of drug and a schedule of treatment to 341 achieve the smallest volume of tumor, the lowest proportion of resistant cells, or in be-342 tween points that balance the trade-off between these outcomes. 343
344
The 2D co-culture system with chemosensitive and chemoresistant cells can be 345 optimized to create spatial heterogeneity found in 3D tumors 346
Here, we tested if growth of chemo-resistant cell populations can be affected by the 347 spatial organization of chemo-sensitive cells in our co-culture system. We observed that 348 the chemoresistant cell's growth was constrained by surrounding chemosensitive cells 349 and the constrained growth was largely depended on their inoculated location (Fig 6, ence between the complete and semi-constrained scenarios was more obvious when 356 two resistant cell subpopulations were inoculated in the same colony (Fig S7) . Hence, 357 our 2D co-culture system can be optimized to imitate various tumor architectures with 358 different layers of spatial heterogeneity. 
